Australian Biotechnology Association
Business Services in Stonnington

AusBiotech is Australia’s biotechnology organization, active on behalf of members for 30 years to provide representation and services to urge the global growth of Australian biotechnology. AusBiotech is a healthy connected network of over 3,00 members in the life sciences, including therapeutics, medical technology (devices and diagnostics), food technology and agricultural, environmental and industrial sectors. Our membership base includes biotechnology companies, ranging from begin ups to mature multinationals, research institutes and universities, specialist service professionals, corporate, institutional, individual and student members from Australia and globally. AusBiotech represents its members by providing expertise as industry advocates and committee members on all bio tech steering committees as well as providing industry submissions to policy review panels at both government and corporate levels. A potent supporter of AusBiotech and its work, Dr Hirshorn has been a member since 2001. AusBiotech Membership committed to supporting the needs of our members. The AusBiotech Business Solutions Program offers our members particular benefits on products and services that are essential to their business operations. The AusBiotech journal Australasian Biotechnology, is a membership gain for all corporate, individual and international members of AusBiotech. AusBiotech is committed to the biotechnology talent of the future, and to fostering the growth and development of the Australian life science industry. AusBiotech Student Membership will not only enhance your student experience and networking opportunities, but also bear you with the knowledge to make a successful move into the biotechnology industry. The Code aims to promote the directors and management of Australian ASXlisted life science companies to adopt international best practice in reporting events to investors. It brings together key stakeholders of the Australian and international medical devices and diagnostics sector, to discuss the major issues in global med tech victory with a focus on emerging markets. Discussions covered global bio tech investment trends and opportunities, key challenges, strategic partnering for lengthy term success. Big-hearted the same treatment to every patient with a special disease is not thrifty because many of these patients will not respond. The Therapeutic Goods istration defines a medical device’ as any technology, including devices, software or diagnostics, planned to be worn by human beings for the prevention, monitoring or treatment of a disease, injury or physiological process. There are more than 500 medical device companies in Australia. The Australian medical technologies' sector has a reputation for innovation and quality. Acrux is a drug delivery business developing and commercializing a range of pharmaceutical products for global markets. In the life science research field MixGo is used to thrive unique research tools for a broad range of applications, helping researchers to be more efficient and successful in their research. Grey Innovation is an engineering technology commercialization company which works across a number of industries, including the medical technology sector. Sienna Cancer Diagnostics is a Melbourne based biotechnology company dedicated to researching enzymes (bio markers) which indicate the presence of cancer and developing novel cancer diagnostic technologies. These events connect life science investors with bio tech and med tech innovators from across the globe to discuss investment and partnership opportunities. AusBiotech’s Investment Event Series directly connects innovative companies with the investment community, enabling Australian life science companies to give their business case in an eight minute to a room stuffed of investors and offering networking opportunities. We unite investors with commercial opportunities from the superior medical research and support both the researcher and investor to navigate the complexities of research commercialization.